XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2023
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lynparza$275 $266 
Alliance revenue - Koselugo23 9 
Total alliance revenue$298 $275 
Cost of sales (1)
70 299 
Selling, general and administrative47 44 
Research and development21 26 
($ in millions)March 31, 2023December 31, 2022
Receivables from AstraZeneca included in Other current assets
$303 $303 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
21 123 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 600 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lenvima$232 $227 
Cost of sales (1)
126 53 
Selling, general and administrative51 31 
Research and development39 57 
($ in millions)March 31, 2023December 31, 2022
Receivables from Eisai included in Other current assets
$244 $214 
Payables to Eisai included in Accrued and other current liabilities (2)
125 — 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Adempas/Verquvo$99 $72 
Net sales of Adempas recorded by Merck59 61 
Net sales of Verquvo recorded by Merck7 3 
Total sales$165 $136 
Cost of sales (1)
57 50 
Selling, general and administrative33 23 
Research and development25 17 
($ in millions)March 31, 2023December 31, 2022
Receivables from Bayer included in Other current assets
$142 $143 
Payables to Bayer included in Accrued and other current liabilities
68 80 
(1)    Includes amortization of intangible assets.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Net sales of Lagevrio recorded by Merck
$392 $3,247 
Cost of sales (1)(2)
221 1,726 
Selling, general and administrative (2)
27 35 
Research and development (2)
16 25 
($ in millions)March 31, 2023December 31, 2022
Payables to Ridgeback included in Accrued and other current liabilities (3)
$191 $348 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses include an allocation for overhead charges.
(3)    Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.